Literature DB >> 25828085

Ofatumumab and its role as immunotherapy in chronic lymphocytic leukemia.

Suneet Sandhu1, Stephen P Mulligan2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25828085      PMCID： PMC4380711          DOI： 10.3324/haematol.2015.124107

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Authors:  M Hallek; K Fischer; G Fingerle-Rowson; A M Fink; R Busch; J Mayer; M Hensel; G Hopfinger; G Hess; U von Grünhagen; M Bergmann; J Catalano; P L Zinzani; F Caligaris-Cappio; J F Seymour; A Berrebi; U Jäger; B Cazin; M Trneny; A Westermann; C M Wendtner; B F Eichhorst; P Staib; A Bühler; D Winkler; T Zenz; S Böttcher; M Ritgen; M Mendila; M Kneba; H Döhner; S Stilgenbauer
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

2.  The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

Authors:  Jessica L Teeling; Wendy J M Mackus; Luus J J M Wiegman; Jeroen H N van den Brakel; Stephen A Beers; Ruth R French; Tom van Meerten; Saskia Ebeling; Tom Vink; Jerry W Slootstra; Paul W H I Parren; Martin J Glennie; Jan G J van de Winkel
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

3.  Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.

Authors:  William G Wierda; Thomas J Kipps; Jan Dürig; Laimonas Griskevicius; Stephan Stilgenbauer; Jirí Mayer; Lukás Smolej; Georg Hess; Rasa Griniute; Francisco J Hernandez-Ilizaliturri; Swaminathan Padmanabhan; Michele Gorczyca; Chai-Ni Chang; Geoffrey Chan; Ira Gupta; Tina G Nielsen; Charlotte A Russell
Journal:  Blood       Date:  2011-04-15       Impact factor: 22.113

4.  Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

Authors:  Valentin Goede; Kirsten Fischer; Raymonde Busch; Anja Engelke; Barbara Eichhorst; Clemens M Wendtner; Tatiana Chagorova; Javier de la Serna; Marie-Sarah Dilhuydy; Thomas Illmer; Stephen Opat; Carolyn J Owen; Olga Samoylova; Karl-Anton Kreuzer; Stephan Stilgenbauer; Hartmut Döhner; Anton W Langerak; Matthias Ritgen; Michael Kneba; Elina Asikanius; Kathryn Humphrey; Michael Wenger; Michael Hallek
Journal:  N Engl J Med       Date:  2014-01-08       Impact factor: 91.245

5.  Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study.

Authors:  V Goede; K Fischer; A Engelke; R Schlag; S Lepretre; L F C Montero; M Montillo; C Fegan; E Asikanius; K Humphrey; G Fingerle-Rowson; M Hallek
Journal:  Leukemia       Date:  2015-01-30       Impact factor: 11.528

6.  Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Authors:  Luciano J Costa; Suzanne R Fanning; Joe Stephenson; Lawrence B Afrin; Emily Kistner-Griffin; Tricia A Bentz; Robert K Stuart
Journal:  Leuk Lymphoma       Date:  2015-03

7.  Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.

Authors:  William G Wierda; Thomas J Kipps; Jirí Mayer; Stephan Stilgenbauer; Cathy D Williams; Andrzej Hellmann; Tadeusz Robak; Richard R Furman; Peter Hillmen; Marek Trneny; Martin J S Dyer; Swami Padmanabhan; Magdalena Piotrowska; Tomas Kozak; Geoffrey Chan; Randy Davis; Nedjad Losic; Joris Wilms; Charlotte A Russell; Anders Osterborg
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

8.  Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.

Authors:  Bertrand Coiffier; Stéphane Lepretre; Lars Møller Pedersen; Ole Gadeberg; Henrik Fredriksen; Marinus H J van Oers; James Wooldridge; Janusz Kloczko; Jerzy Holowiecki; Andrzej Hellmann; Jan Walewski; Mimi Flensburg; Jørgen Petersen; Tadeusz Robak
Journal:  Blood       Date:  2007-11-14       Impact factor: 22.113

9.  Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.

Authors:  Jessica L Teeling; Ruth R French; Mark S Cragg; Jeroen van den Brakel; Marielle Pluyter; Haichun Huang; Claude Chan; Paul W H I Parren; C Erik Hack; Michael Dechant; Thomas Valerius; Jan G J van de Winkel; Martin J Glennie
Journal:  Blood       Date:  2004-06-01       Impact factor: 22.113

10.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Authors:  John C Byrd; Jennifer R Brown; Susan O'Brien; Jacqueline C Barrientos; Neil E Kay; Nishitha M Reddy; Steven Coutre; Constantine S Tam; Stephen P Mulligan; Ulrich Jaeger; Steve Devereux; Paul M Barr; Richard R Furman; Thomas J Kipps; Florence Cymbalista; Christopher Pocock; Patrick Thornton; Federico Caligaris-Cappio; Tadeusz Robak; Julio Delgado; Stephen J Schuster; Marco Montillo; Anna Schuh; Sven de Vos; Devinder Gill; Adrian Bloor; Claire Dearden; Carol Moreno; Jeffrey J Jones; Alvina D Chu; Maria Fardis; Jesse McGreivy; Fong Clow; Danelle F James; Peter Hillmen
Journal:  N Engl J Med       Date:  2014-05-31       Impact factor: 91.245
View more
  4 in total

1.  miR-218 inhibits acute promyelocytic leukemia cell growth by targeting BMI-1.

Authors:  Yan Wang; Hai-Hong Sun; Ming-Hua Sui; Jun-Jie Ma
Journal:  Oncol Lett       Date:  2017-10-19       Impact factor: 2.967

Review 2.  Immunotherapy in Chronic Lymphocytic Leukaemia (CLL).

Authors:  Ciara L Freeman; John G Gribben
Journal:  Curr Hematol Malig Rep       Date:  2016-02       Impact factor: 3.952

Review 3.  Ofatumumab - a valid treatment option for chronic lymphocytic leukemia patients.

Authors:  Salma M AlDallal
Journal:  Ther Clin Risk Manag       Date:  2017-07-20       Impact factor: 2.423

4.  Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies.

Authors:  Mitchell Evers; Toine Ten Broeke; J H Marco Jansen; Maaike Nederend; Firas Hamdan; Karli R Reiding; Saskia Meyer; Petra Moerer; Iris Brinkman; Thies Rösner; Robert Jan Lebbink; Thomas Valerius; Jeanette H W Leusen
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.